Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04519437 · ClinicalTrials.gov registry record · Phase 1
Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19
A Phase 1 study of Healthy and Chronic Stable Illness, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 974
- Enrollment target
- 7
- Study locations
NCT04519437: Completed Phase 1 study of Healthy and Chronic Stable Illness, sponsored by Regeneron Pharmaceuticals.
NCT04519437 is a Phase 1 study of Healthy and Chronic Stable Illness that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 974 participants, above the 646-participant average among 1,090 other Healthy trials with a reported enrollment target (51% higher). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04519437, a Phase 1 study of Healthy and Chronic Stable Illness, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 974 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary objectives are: * To assess the occurrence of adverse events of special interest (AESIs) in participants treated with repeated subcutaneous (SC) doses of REGN10933+REGN10987 compared to placebo * To assess the concentrations of REGN10933 and REGN10987 in serum over time after single and repeated SC administration The secondary objectives are: * To assess the safety and tolerability of repeated SC doses of REGN10933+REGN10987 compared to placebo * To assess attainment of target concentrations of REGN10933 and REGN10987 in serum after single and repeated SC administration * To assess the immunogenicity of REGN10933 and REGN10987
Conditions Studied
Interventions
- DRUG Placebo
- DRUG REGN10933+REGN10987
Study Locations (7)
Arizona
- Regeneron Study Site - Tempe
Arkansas
- Regeneron Study Site - Rogers
California
- Regeneron Study Site - Sacramento
Florida
- Regeneron Study Site - Miami
Nebraska
- Regeneron Study Site - Lincoln
Ohio
- Regeneron Study Site - Dayton
Texas
- Regeneron Study Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 974 participants |
| Start Date | 2020-07-26 |
| Est. Completion | 2021-11-22 |
| Phase | Phase 1 |
What the finished NCT04519437 record still lists
NCT04519437 is an interventional study that assigns participants to a tested intervention. The registered 974 participants enrollment target is mid-sized for trials with a published cap, above the 646-participant average among 1,090 other Healthy trials with a reported enrollment target (51% higher).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04519437 lists 7 locations in 7 states (Arizona, Arkansas, California).
Frequently Asked Questions
What is clinical trial NCT04519437 about?
NCT04519437 is a clinical study titled "Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19". The primary objectives are: * To assess the occurrence of adverse events of special interest (AESIs) in participants treated with repeated subcutaneous (SC) doses of REGN10933+REGN10987 compared to placebo * To assess the concentrations of REGN10933 and REGN10987 in serum over time after single and...
What is the current status of trial NCT04519437?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 974 participants. The study started on 2020-07-26. Estimated completion is 2021-11-22.
What conditions does trial NCT04519437 study?
This clinical trial studies the following conditions: Healthy, Chronic Stable Illness.
What interventions are being tested in trial NCT04519437?
The interventions under investigation include: Placebo (DRUG), REGN10933+REGN10987 (DRUG).
Who is sponsoring clinical trial NCT04519437?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04519437 being conducted?
This trial has 7 study locations across Arizona, Arkansas, California, Florida, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04519437's enrollment target sits among peer trials
974 31st of 1090 higher than 1,060 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06948422 · 974 participants · Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- NCT06820736 · 975 participants · NA
A Prospective, Randomized Comparison Of Drainage Techniques After One- Or Two-Level Open Posterior Lumbar Decompression Or Decompression And Fusion
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI